Top Markets
#1 Akedo Akedo +69.97%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.06%
#4 Cross Cross +36.90%
#5 Velvet Velvet +31.95%
#6 Black Phoenix Black Phoenix +26.64%
#7 Cap Cap +22.61%
#8 OVERTAKE OVERTAKE +19.97%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +14.79%
#10 Ontology Gas Ontology Gas +11.65%
Coin of the day
Akedo Akedo
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Lipidor AB (publ) Lipidor AB (publ)

Lipidor AB (publ)

LIPI
Rang in Aktien #39103
Lipidor AB (publ), a Swedish pharmaceutical company founded in Danderyd in... Lipidor AB (publ), a Swedish pharmaceutical company founded in Danderyd in 2009, specializes in developing medicinal products. Its core business centers on creating treatments for various skin conditions, including psoriasis, bacterial skin infections, and atopic dermatitis. The company's product pipeline includes AKP-01, which is currently in Phase III clinical trials for psoriasis, while other formulations like AKP-02 (also for psoriasis) and AKP-03 and AKP-07 (for eczema) are in earlier, preclinical development stages. Beyond its own drug candidates, Lipidor manufactures and supplies active pharmaceutical ingredients (APIs). These APIs are incorporated into products addressing a broad spectrum of therapeutic applications, such as managing psoriasis, microbial infections, inflammation, fungal issues, local pain relief, acne, wound healing, eczema, and migraines. Lipidor also caters to the animal health market, offering a line of spray-on skin care products for dogs, cats, and horses. Additionally, it develops consumer health items designed for purposes like antibacterial action, antiseptic care, moisturizing, disinfection, and treating acne and warts. In a key strategic alliance, Lipidor has partnered with Cannassure Therapeutics Ltd. This collaboration aims to advance topical medicinal cannabis products specifically formulated to alleviate skin inflammations and psoriatic lesions.
Aktienkurs
$0.02243487
Zuletzt synchronisiert: 2025-06-04
Marktkapitalisierung
$650.09K
Veränderung (1 Tag)
0.39%
Veränderung (1 Jahr)
0.00%
Land
SE
Handel Lipidor AB (publ) (LIPI)

Kategorie

Healthcare
Gewinn für Lipidor AB (publ) (LIPI)
Gewinn im Dec 2024 TTM: $-1.25M
Laut den aktuellen Finanzberichten von Lipidor AB (publ) betragen die aktuellen Gewinne des Unternehmens $-1.25M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $-1.14M, eine Steigerung gegenüber dem Gewinn im Jahr 2022, der $-3.97M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Lipidor AB (publ) von 2016 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
2026 (TTM) $-1.25M 0.00%
2024 $-1.25M 9.96%
2023 $-1.14M -71.31%
2022 $-3.97M 68.68%
2021 $-2.35M 19.98%
2020 $-1.96M 32.57%
2019 $-1.48M 73.02%
2018 $-854.84K 129.77%
2017 $-372.04K -30.69%
2016 $-536.78K 0.00%
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
$33.59B -2,683,842.70%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
$25.20B -2,012,923.00%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
$8.70B -695,033.61%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
$21.39B -1,708,738.18%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
$5.95B -475,265.55%
US